iFluor 555酰肼

简要概述

产品基本信息

货号：1083

产品名称：iFluor 555酰肼

规格：1mg

储存条件：-15℃避光防潮

保质期：12个月

产品物理化学光谱特性

分子量：839.83

溶剂：DMSO

激发波长（nm）：552

发射波长（nm）：567

产品介绍

        iFluor 555酰肼是美国AAT Bioquest生产的iFluor系列荧光染料。AAT Bioquest的iFluor 染料经过优化，可用于标记蛋白质，特别是抗体。这些染料是明亮的，光稳定的并且对蛋白质具有 小的猝灭。荧光仪器的主要激光线（例如，350,405,488,555和633nm）可以很好地激发它们。 iFluor 555染料的荧光激发和发射 值分别为~550nm和~570nm。 iFluor 555系列的光谱特性基本上与Cy3®相同（Cy3®是GE Healthcare的商标）。与Cy3探针相比，iFluor 555家族具有更强的荧光和更高的光稳定性。它们的荧光与pH值无关，pH值为3至11.这些光谱特性使这种新型染料系列成为Cy3®的优良替代品。 iFluor 555系列已成为Cy3®和AlexaFluor®555标记染料（Cy3®和AlexaFluor®是Invitrogen和GE Health Care的商标）的替代品。 iFluor 555酰肼相当稳定，与羰基（如醛）具有良好的反应性和选择性。百萤生物是AAT Bioquest的中国代理商，为您提供优质的iFluor 555酰肼。 

参考文献

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer
Authors: O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J.
Journal: Cancer Chemother Pharmacol (2007): 79

Mutational Patterns Associated with the 69 Insertion Complex in Multi-drug-resistant HIV-1 Reverse Transcriptase that Confer Increased Excision Activity and High-level Resistance to Zidovudine
Authors: Cases-Gonzalez CE, Franco S, Martinez MA, Menendez-Arias L.
Journal: J Mol Biol (2007): 298

A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab
Authors: Nakajima H, Mizuta N, Mizuta M, Nakatsukasa K, Kobayashi A, Hachimine Y, Sakaguchi K, Fujiwara I, Sawai K.
Journal: Gan To Kagaku Ryoho (2006): 1305

A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis
Authors: Zhu LZ, Fu Y, Chu NH, Ye ZZ, Xiao HP, Wang W, Yuan SL, Zhang X, Luo YA, Ma LP.
Journal: Zhonghua Jie He He Hu Xi Za Zhi (2006): 520

Activity-guided isolation of scopoletin and isoscopoletin, the inhibitory active principles towards CCRF-CEM leukaemia cells and multi-drug resistant CEM/ADR5000 cells, from Artemisia argyi
Authors: Adams M, Efferth T, Bauer R.
Journal: Planta Med (2006): 862

Advances in the study of drugs for the treatment of multi-drug resistant tuberculosis
Authors: Tang SJ.
Journal: Zhonghua Jie He He Hu Xi Za Zhi (2006): 567

Assessment of resistance in multi drug resistant tuberculosis patients
Authors: Irfan S, Hassan Q, Hasan R.
Journal: J Pak Med Assoc (2006): 397

Bacteriologic profile of bacteremia due to multi-drug resistant bacteria at Charles-Nicolle Hospital of Tunis
Authors: Saidani M, Boutiba I, Ghozzi R, Kammoun A, Ben Redjeb S.
Journal: Med Mal Infect (2006): 163

Clinical Prediction Tool to Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multi-Drug Resistance
Authors: Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro B, Graffunder E, McNutt LA.
Journal: Antimicrob Agents Chemother. (2006)

Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection
Authors: Biancofiore G, Tascini C, Bisa M, Gemignani G, Bindi ML, Leonildi A, Giannotti G, Menichetti F.
Journal: Minerva Anestesiol. (2006)